Smith & Nephew H1 FY26 trading profit rises 8.1% to $566 million
SNN•Revenue growth slows in Q2
Underlying revenue growth was 1.6% in Q2, with softness in U.S. Orthopaedics and Advanced Wound Bioactives.
H1 trading profit and EPS rise
Smith & Nephew H1 trading profit rose 8.1% to $566 million.
Adjusted EPS climbed 11.0% to 47.7.
Full-year outlook cut but profit guidance maintained
The company cut its full-year revenue outlook, now expecting about 4.0% growth, while maintaining guidance for trading profit, free cash flow and ROIC.
It also added $50 million of 2026 savings to offset lower revenue growth, and H1 trading cash conversion fell to 77%.




